Aqara To Unveil New Smart Home Devices at IFA 2023, Embracing the Future of Connected Living
31.8.2023 10:00:00 EEST | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its attendance at this year’s IFA show, where it will unveil multiple new smart home devices. These include the Smart Lock U200, the Camera E1, the Dual Relay Module T2, the Ceiling Light T1M, and an EU-style wall outlet. Aqara will be showcasing these new devices along with other smart home technology and solutions at its booth (H22, 214).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831580646/en/
Aqara unveils new smart home devices at IFA 2023 (Photo: Business Wire)
With a commitment to making smart home technology more accessible to households worldwide, Aqara continues to expand its product portfolio to enable various home automation use cases. The five new products previewed at IFA are expected to become available for order in the coming months.
Smart Lock U200 - As a retrofit solution, Aqara’s new Smart Lock U200 offers the convenience of keyless home access to a broad user base. The lock operates with existing cylinders and requires no drilling or door modifications. As Aqara’s first Matter-over-Thread smart lock, the U200 will be interoperable with a wide array of smart home ecosystems and products. Using an Aqara NFC card or specified NFC-enabled mobile devices, users can unlock easier than ever before. Other secure access options include auto-unlock, fingerprints, PIN codes and mobile apps. Aqara also plans to initiate its first crowdfunding campaign on Kickstarter for the Smart Lock U200 later this year.
Camera E1 - Aqara is expanding its home surveillance camera portfolio with the 2K, Pan/Tilt Camera E1. Similar to other indoor home cameras from the Company, this new camera supports major third-party platforms like Apple Home (including HomeKit Secure Video), Amazon Alexa, and Google Home. Built upon Wi-Fi 6 and Bluetooth 5.2, the camera enables smoother live view and easier pairing experience. Other features of the E1 camera include AI-enabled person detection, person tracking and flexible storage options such as cloud storage, microSD card, and NAS storage.
Dual Relay Module T2 - The Dual Relay Module T2 is a versatile solution for home automation, allowing easy control of various devices ranging from lights, motorized window coverings, garage doors, boilers, to electric heaters and underfloor heating. Built upon Zigbee 3.0, the dual relay module features Matter-over-bridge support and is compatible with major third-party platforms. It also allows users to monitor energy consumption and ensures peace of mind with safety features like overheat protection, overload protection, and configurable power limits. Powered by AC (100-250V) or DC (24-60V), the 2-channel relay supports a total (and per-channel) loads of up to 10 Amps.
Ceiling Light T1M - Following the LED Strip T1, which was announced in August 2023, Aqara is introducing its second smart lighting device to the global market. With an approximate diameter of 50 centimeters, the Ceiling Light T1M offers a broad spectrum of hues from dimmable whites to 16 million vibrant colors, allowing users to set the atmospheric lighting for different occasions and moods. Additional features include an independently addressable RGB ring for gradient effects and integration into home automation, such as using the RGB ring as a status light to indicate potential threats like an open door or water leak. Similar to other Zigbee devices from Aqara, the Ceiling Light T1M features the low idle consumption, Matter-over-bridge support, and the wide compatibility with major platforms.
EU-style wall outlet - Finally, Aqara is introducing a smart wall socket for the EU market. This outlet allows easy control of plugged devices via mobile apps, voice assistants and home automation. It also helps users track energy consumption. Moreover, this new outlet can be configured to sense and report the status of the plugged device, making it possible to use the on/off status of an appliance as an automation trigger. For example, to close the curtains and dim the lights when the TV is turned on, or to notify the user when the washing machine finished the laundry. As a repeater of the Zigbee network, this socket outlet also enhances network reliability and responsiveness of other compatible smart home devices.
“Aqara is at the forefront of innovating the smart home experience, and these new products are a testament to our dedication. Each of them is crafted with the user's convenience and lifestyle in mind, reflecting our commitment to quality and innovation,” said Cathy You, Aqara Senior Vice President, Global Business and Strategy. “We invite everyone to join us at our booth to experience firsthand the future we're building together.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831580646/en/
Contact information
For Media Inquiries:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom